Centrum Rozwoju Polskich Technologii Spółka z Ograniczoną Odpowiedzialnością (KRS 0000844513, NIP 9710728655) is a Polish company, headquartered in Bolesławów, Mazowieckie voivodeship. Centrum Rozwoju Polskich Technologii operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since June 4, 2020. Centrum Rozwoju Polskich Technologii's most recently reported net revenue was 86.7 K PLN for 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Centrum Rozwoju Polskich Technologii
Identity
- Name
- Centrum Rozwoju Polskich Technologii Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 4, 2020
- Registry status as of
- November 21, 2025
- Latest entry
- July 28, 2025
- Founding act
- 17.04.2020 R., REP. A NR 1610/2020, NOTARIUSZ KONRAD FILOCHOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE
Articles of association history (2)
- April 17, 2020: 17.04.2020 R., REP. A NR 1610/2020, NOTARIUSZ KONRAD FILOCHOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE
- April 22, 2021: 22.04.2021, NOTARIUSZ KONRAD FILOCHOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, REP A NR 1967/2021- ZMIANA §2 UST 1 I 2, §5, §6, §39 UST 2 UMOWY SPÓŁKI
Activities
Other activities
Address and contact
- Address
- 16A, 09-500, BOLESŁAWÓW, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- GOSTYNIŃSKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.4459, 19.5407approx.
Risk and payment profile - Centrum Rozwoju Polskich Technologii
Credibility rating
75.2 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/6 yrs
Board changes
0
0/6 yrs
PKD changes
1
1/6 yrs
Name changes
1
1/6 yrs
Data from 6 years of registry activity.
Credibility history
Payment reliability score from 2020–2024
Current: B (75/100)
Trend: improving (+5.5 pts/year)
High payment credibility - the company's financial condition is good and the risk of cooperating with it is low.
Trade credit limit history
Standard limit from 2020–2024
Current: 16.6 K PLN
Safe: 10.8 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Centrum Rozwoju Polskich Technologii
Founded
June 4, 2020
6 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
BOLESŁAWÓW
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
50 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
5 years
2020–2024 · profitable: 4/5
Registry entries
15
latest: July 28, 2025
Revenue
86.7 K PLN
2024
Net profit
26.4 K PLN
2024
Assets
277.8 K PLN
2024
Equity
269.0 K PLN
2024
Valuation
180.2 K PLN
Medium confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Centrum Rozwoju Polskich Technologii.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
